EU approves Amgen's bone drug Xgeva for cancer patients

07/18/2011 | InPharm.com

European regulators approved Amgen's Xgeva, or denosumab, for preventing fractures and other skeletal events in adults with solid tumors. The approval provides Amgen another year of market exclusivity. Denosumab also is marketed as Prolia for osteoporosis.

View Full Article in:

InPharm.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health